p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription

Journal of Cellular Physiology

Volumn 208, Issue 1, 2006, Pages 246-252

  Wang, Chie Hong ^a   Chang, Hui Chiu ^b   Hung, Wen Chun ^a,c  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; GELATINASE A; GENE PRODUCT; MESSENGER RNA; PROTEIN P16; TRANSCRIPTION FACTOR SP1;

ARTICLE; CANCER INVASION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONSENSUS SEQUENCE; DNA BINDING; GENE DELETION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

CYCLIN A; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 33744930117     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.20660     Document Type: Article

References (34)

1. Brew K, Dinakarpandian D, Nagase H. 2000. Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochem Biophys Acta 1477:267-283.
2. Callejas NA, Casado M, Diaz-Guerra MJM, Bosca L, Martin-Sanz P. 2001. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33:860-867.
3. Caterina JJ, Yamada S, Caterina NC, Longenecker G, Holmback K, Shi J, Yermovsky AE, Engler JA, Birkedal-Hansen H. 2000. Inactivating mutation of the mouse tissue inhibitor of metalloproteinases-2 (Timp-2) gene alters proMMP-2 activation. J Biol Chem 275:26416-26422.
4. Chambers AF, Matrisian LM. 1997. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89:1260-1270.
5. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WKA, Sawaya R, Kyritsis AP, Rao JS. 1997. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15:2049-2057.
6. Chu S, Ferro TJ. 2005. Sp1: Regulation of gene expression by phosphorylation. Gene 348:1-11.
7. Dai CY, Enders GH. 2000. p16 INK4a can initiate an autonomous senescence program. Oncogene 19:1613-1622.
8. Fahraeus R, Lane DP. 1999. The p16 (INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 18:2106-2118.
9. Fojas de Borja P, Collins NK, Du P, Azizkhan-Clifford J, Mudryj M. 2001. Cyclin A-CDK phosphorylates Sp1 and enhances Sp1-mediated transcription. EMBO J 20:5737-5747.
10. Harada H, Nakagawa K, Iwata S, Saito M, Kumon Y, Sakaki S, Sato K, Hamada K. 1999. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59:3783-3789.
11. Huang YC, Chen JY, Hung WC. 2004. Vitamin D3 receptor/Sp1 complex is required for the induction of p27Kip1 expression by vitamin D3. Oncogene 23:4856-4861.
12. Irwin JC, Kirk D, Gwatkin RB, Navre M, Cannon P, Giudice LC. 1996. Human endometrial matrix metalloproteinase-2, a putative menstrual proteinase. Hormonal regulation in cultured stromal cells and messenger RNA expression during the menstrual cycle. J Clin Invest 97:438-447.
13. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RD, III, Johnson BE, Skolnick MH. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
14. Kim O, Park M, Kang H, Lim S, Lee CT. 2003a. Differential protein expressions induced by adenovirus-mediated p16 gene transfer into Balb/c nude mouse. Proteomics 3:2412-2419.
15. Kim SK, Wang KC, Cho BK, Lim SY, Kim YY, Oh CW, Chung YN, Kim CY, Lee CT, Kim HJ. 2003b. Adenoviral p16/CDKN2 gene transfer to malignant glioma: Role of p16 in growth, invasion, and senescence. Oncol Rep 10:1121-1126.
16. Kleiner DE, Jr., Stetler-Stevenson WG. 1993. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 5:891-897.
17. Liu LT, Chang HC, Chiang LC, Hung WC. 2003. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63:3069-3072.
18. McConnell BB, Gregory FJ, Stott FJ, Hara E, Peters G. 1999. Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 19:1981-1989.
19. Nagase H, Woessner JF, Jr. 1999. Matrix metalloproteinases. J Biol Chem 274:21491-21494.
20. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756.
21. Pan MR, Hung WC. 2002. Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277:32775-32780.
22. Qin H, Moellinger JD, Wels A, Windsor LJ, Sun Y, Meltzer SJ. 1998. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma. J Immunol 161:6664-6673.
23. Qin H, Sun Y, Benveniste EN. 1999. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274:29130-29137.
24. Ricke WA, Smith GW, Reynolds LP, Redmer DA, Smith MF. 2002. Analysis of luteal tissue inhibitor of metalloproteinase-1, -2, and -3 during prostaglandin F(2alpha)-induced luteolysis. Bio Reprod 66:1083-1094.
25. Rocco JW, Li D, Liggett WH, Jr., Duan L, Saunders JK, Jr., Sidransky D, O'Malley BW, Jr. 1998. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4:1697-1704.
26. Serrano M, Hannon GJ, Beach D. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
27. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
28. Spruck CH, III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA. 1994. p16 gene in uncultured tumours. Nature 370:183-184.
29. Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y. 2000. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther 7:360-372.
30. Stetler-Stevenson WG, Hewitt R, Corcoran M. 1996. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin Cancer Biol 7:147-154.
31. Wang Z, Juttermann R, Soloway PD. 2000. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 275:26411-26415.
32. Uhm JH, Dooley NP, Villemure JG, Yong VW. 1996. Glioma invasion in vitro: Regulation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 14:421-433.
33. Uhrbom L, Nister M, Westermark B. 1997. Induction of senescence in human malignant glioma cells by p16INK4A. Oncogene 15:505-514.
34. Young KA, Hennebold JD, Stouffer RL. 2002. Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. Mol Hum Reprod 8:833-840.